Date：28 July (Thursday)
Time: 10:40 – 12:00 (GMT+8)
Rasmus is a globally recognised expert on scientific information and knowledge dissemination. He spent his earlier career as a Fortune500 strategist. Rasmus is a strong believer in the power of accurate information and new ideas - he founded his first, short lived, newspaper at the age of 13 - a passion that drove him to found Airfinity. As CEO of Airfinity he is often quoted in leading media companies such as the Financial Times, Bloomberg and CNN and has emerged as leading voice on COVID-19 pandemic response. Rasmus holds a B.Sc. in Political Science, a MPA from Harvard University and is a recipient of the Crown Prince Frederic award for excellent scholarship. He lives in London.
Stopping the Next Pandemic Before It Starts
Pandemics, particularly those such as COVID-19, have been challenging to predict with their numerous uncertainties and continuously emerging new variants and threats. The time lag between identifying and designating new variants of concern has frequently taken too long and indicates the significant threat, should a new variant be more transmissible, more virulent, or elicits significant immune escape. In fact, the time-lags between identifying and designating new variants of concern together with waning immunity, and the significant reduction in testing levels since the start of the year indicates the pandemic threat still remains. At Airfinity, we are able to track, capture, and structure thousands of daily data points, finding the trends in the data using our expert knowledge to project forwards developing valuable insights, and dynamic Global vaccine and market forecasts that continuously update and improve over time with each new data point. As we observe production output reduce, there are still potential spare capacities which have been built across all technology types – capacities that can be utilised for future pandemics and able to unprecedentedly scale-up vaccine production. An example we will be looking at is that of the emergence of Monkeypox, which has spread rapidly across non-endemic countries, and now fuelling the demand of securing any available vaccines.